



Quotient  
Sciences

Assess. Adapt. Accelerate.

## Pharmaterials rebrands to Quotient Sciences

**Nottingham, U.K., Apr. 05, 2018** — [Quotient Sciences](#) (“Quotient”), the drug development services organization, announces that it has completed the integration and rebrand of Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K.

Pharmaterials, now named Quotient Sciences (Reading) Limited, will play a key role in expanding and strengthening Quotient’s service portfolio from preclinical formulation development through to commercial manufacturing, and support the continued growth of Quotient’s [Translational Pharmaceutics](#)® platform.

The Reading business has a strong reputation in the development of small molecule drug products for oral and inhaled delivery and bolsters Quotient’s formulation development and manufacturing services. The 48,000 sq ft. facility includes an additional 13 GMP manufacturing suites, high potency containment capabilities and expertise across all key solubilisation technologies including spray drying, hot melt extrusion, lipidic systems and micronization.

Quotient Sciences continues to focus on delivering an innovative portfolio of services that are proven to shorten development timelines, reduce associated costs and accelerate the delivery of new medicines to patients globally.

ENDS

**For further information, please contact:**

**Quotient Sciences**

Robin Bodicoat

Marketing Director

Tel: +44 (0)115 931 5102

Email: [robin.bodicoat@quotientosciences.com](mailto:robin.bodicoat@quotientosciences.com)

**About Quotient Sciences**

Quotient Sciences, a global pharmaceutical development, clinical pharmacology, and clinical and commercial manufacturing organization, delivers innovative, customized solutions for pharmaceutical and biotech customers through both individual and integrated services. Its Translational Pharmaceutics® platform integrates formulation development, real-time adaptive GMP manufacturing and clinical research for the continuous improvement of drug development programs, and is proven to accelerate timelines and reduce cost.

For more information, visit [quotientosciences.com](http://quotientosciences.com).